This is a joint post with Rachel Silverman.
Through our Value for Money working group, we’ve spent much of the past year immersed in the world of global health funding agencies. With so many new agencies, particularly in the last quarter century (Figure 1), understanding the intricacies of the global health family can be daunting, even for the most devoted observers.
Oxfam hasn’t let pesky little things like representative household surveys and impact evaluation results get in the way of their condemnation of Ghana’s health insurance program.
Bill Gates’ effort to close the $2.6 billion funding gap for polio eradication has been accompanied by high-profile coverage at Davos, in The New York Times and even The Daily Show.
How can it be possible, in 2009, that almost half of all Indian children under three years old are underweight or severely underweight, and that child malnutrition accounts for more than one-fifth of the total burden of disease in that country? Something like three-quarters of all preschool children in India have iron-deficiency anemia, which impairs learning, and more than half have at least mild vitamin A deficiency.
A new article in Nature, Malaria breakthrough raises spectre of drug resistance: Yeast engineered to produce potent drug, manages to simultaneously announce exciting scientific progress that will reduce the cost of artemisinin combination therapy (ACTs) for malaria while addressing the potential impact on drug resistance in the same breath :